Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection-Reference-Cited by-同舟云学术

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection

Published:2011-09 Issue:25 Volume:879 Page:2673-2676
ISSN:1570-0232
Container-title:Journal of Chromatography B
language:en
Short-container-title:Journal of Chromatography B

Author:

Stratford Michael R.L.,Folkes Lisa K.

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference9 articles.

1. Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor Vascularity

2. Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results

3. Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography

4. Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High throughput screening of phenolic constituents in a complex sample matrix using post-column derivatisations employing reaction flow HPLC columns;Microchemical Journal;2018-09

2. Post column derivatisation analyses review. Is post-column derivatisation incompatible with modern HPLC columns?;Analytica Chimica Acta;2015-08

3. Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection;Journal of Chromatography B;2012-06

4. A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis–trans isomerisation;Journal of Pharmaceutical and Biomedical Analysis;2012-03

5. Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors;Clinical Cancer Research;2012-01-10